Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 62Recruiting 41Active not recruiting 33Terminated 14Withdrawn 12Unknown 7Not yet recruiting 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 33Magnetic Resonance Spectroscopy 21Biopsy 19Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8Bevacizumab 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Azacitidine 7pembrolizumab 6Radiotherapy 6Radiosurgery 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Surgical Procedures, Operative 5Rituximab 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡